RenovoRx Enrolls First Participant In PRISM-TAMP, “PDAC Regression And Intraoperative Surgical Margin With Neoadjuvant TAMP Study

RenovoRx, Inc. (NASDAQ: RNXT) has announced the enrollment of its first participant in the PRISM-TAMP trial, which focuses on PDAC regression and intraoperative surgical margins with neoadjuvant TAMP treatment. The trial is investigator-initiated and sponsored by the University of Vermont, with a second patient also moving toward treatment shortly after the trial's commencement.